DNA Methylation State of the Galectin-3 Gene Represents a Potential New Marker of Thyroid Malignancy

Overview

Journal Oncol Lett

Specialty Oncology

Date 2013 Aug 16

PMID 23946782

Citations 13

Authors

Simona Keller

Tiziana Angrisano

Ermanno Florio

Raffaela Pero

Miriam Decaussin-Petrucci

Giancarlo Troncone

Mario Capasso

Francesca Lembo

Alfredo Fusco

Lorenzo Chiariotti

Affiliations

Soon will be listed here.

Abstract

In order to supplement the cytopathological assessment of thyroid tumors, there is a need for new markers to correctly diagnose malignant thyroid lesions and avoid unnecessary and potentially harmful therapies for patients. The immunohistochemical expression of galectin-3 is currently considered to be the most accurate stand-alone marker for thyroid cancer diagnosis. The aim of this study was to establish whether the methylation state of the galectin-3 gene is a candidate molecular marker for thyroid malignancy. Thyroid specimens from 50 patients were analyzed, including 5 normal thyroid, 3 goiters, 39 papillary and 3 anaplastic thyroid carcinoma cases. High-resolution methylation analyses was performed to investigate the methylation state of a large genomic region (from -89 to +408) encompassing the galectin-3 transcriptional start site. Within this region, 5 CpG sites (nucleotide positions +134, +137, +142, +147 and +156) were observed to be differentially methylated among the samples and were further analyzed by the quantitative pyrosequencing technique. The hypomethylation of the +134, +137, +142, +147 and +156 CpG sites was observed to be markedly associated with cancer. Although the methylation degree of each single site was highly variable in non-neoplastic tissues, the average methylation state of the 5 CpG sites clearly distinguished cancer from the nonneoplastic thyroid tissues.

Citing Articles

Immunomodulation exerted by galectins: a land of opportunity in rare cancers.

Diaz-Alvarez L, Lopez-Cortes G, Perez-Figueroa E Front Immunol. 2023; 14:1301025.

PMID: 38022609 PMC: 10663293. DOI: 10.3389/fimmu.2023.1301025.

Promoter methylation might shift the balance of Galectin-3 & 12 expression in adult acute myeloid leukemia patients.

Assem M, El-Araby R, Al-Karmalawy A, Nabil R, Kamal M, Belal A Front Genet. 2023; 14:1122864.

PMID: 36861129 PMC: 9968970. DOI: 10.3389/fgene.2023.1122864.

Critical appraisal of epigenetic regulation of galectins in cancer.

Gadwal A, Modi A, Khokhar M, Vishnoi J, Choudhary R, Elhence P Int J Clin Oncol. 2021; 27(1):35-44.

PMID: 34652614 DOI: 10.1007/s10147-021-02048-x.

Urinary Biomarkers: Diagnostic Tools for Monitoring Athletes' Health Status.

Pero R, Brancaccio M, Mennitti C, Gentile L, Arpino S, de Falco R Int J Environ Res Public Health. 2020; 17(17).

PMID: 32825414 PMC: 7503896. DOI: 10.3390/ijerph17176065.

Athlete's Passport: Prevention of Infections, Inflammations, Injuries and Cardiovascular Diseases.

Mennitti C, Brancaccio M, Gentile L, Ranieri A, Terracciano D, Cennamo M J Clin Med. 2020; 9(8).

PMID: 32781561 PMC: 7465786. DOI: 10.3390/jcm9082540.

References

Baylin S, Bestor T . Altered methylation patterns in cancer cell genomes: cause or consequence?. Cancer Cell. 2002; 1(4):299-305. DOI: 10.1016/s1535-6108(02)00061-2. View

Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View

Galusca B, Dumollard J, Lassandre S, Niveleau A, Prades J, Estour B . Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch. 2005; 447(1):18-23. DOI: 10.1007/s00428-005-1268-5. View

Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulie A, Toubert M . Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene. 2007; 26(27):4018-24. DOI: 10.1038/sj.onc.1210178. View

Keller S, Sarchiapone M, Zarrilli F, Tomaiuolo R, Carli V, Angrisano T . TrkB gene expression and DNA methylation state in Wernicke area does not associate with suicidal behavior. J Affect Disord. 2011; 135(1-3):400-4. DOI: 10.1016/j.jad.2011.07.003. View

Baylin S . DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005; 2 Suppl 1:S4-11. DOI: 10.1038/ncponc0354. View

Santoro M, Melillo R, Grieco M, Berlingieri M, Vecchio G, Fusco A . The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 1993; 4(2):77-84. View

HEDINGER C, Williams E, Sobin L . The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989; 63(5):908-11. DOI: 10.1002/1097-0142(19890301)63:5<908::aid-cncr2820630520>3.0.co;2-i. View

Xu X, El-Naggar A, Lotan R . Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995; 147(3):815-22. PMC: 1870977. View

10.

Xing M . Gene methylation in thyroid tumorigenesis. Endocrinology. 2006; 148(3):948-53. DOI: 10.1210/en.2006-0927. View

11.

Xing M . BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12(2):245-62. DOI: 10.1677/erc.1.0978. View

12.

Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra W . Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 2003; 63(9):2316-21. View

13.

Sassa M, Hayashi Y, Watanabe R, Kikumori T, Imai T, Kurebayashi J . Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. Thyroid. 2011; 21(5):511-7. DOI: 10.1089/thy.2010.0295. View

14.

Gharib H . Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc. 1994; 69(1):44-9. DOI: 10.1016/s0025-6196(12)61611-5. View

15.

Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R . Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008; 9(6):543-9. DOI: 10.1016/S1470-2045(08)70132-3. View

16.

Chiu C, Strugnell S, Griffith O, Jones S, Gown A, Walker B . Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010; 176(5):2067-81. PMC: 2861072. DOI: 10.2353/ajpath.2010.090353. View

17.

De Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G . Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer. 2002; 86(6):917-23. PMC: 2364158. DOI: 10.1038/sj.bjc.6600156. View

18.

Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T . Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest. 2009; 89(7):791-9. DOI: 10.1038/labinvest.2009.50. View

19.

Elisei R, Shiohara M, Koeffler H, Fagin J . Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 1998; 83(10):2185-93. View

20.

Catalano M, Fortunati N, Boccuzzi G . Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne). 2012; 3:40. PMC: 3355953. DOI: 10.3389/fendo.2012.00040. View